13. LITERATUR
13.1 Allgemeine Literatur
| [1] |
Breitenecker G, Lax S. Tumoren des Corpus
uteri. in: Holzner JH et al. (ed.) Histologische Tumorklassifikation
der Österreichischen Gesellschaft für Pathologie. Springer
Verlag 1994. |
| [2] |
Gompel C, Silverberg St G. Pathology in
Gynecology and Obstetrics. 4th edition. Chapter 4, The
Corpus Uteri pp163-284. J B Lippincott Company, Philadelphia,
1994. |
| [3] |
Scully RE (editor). Histological Typing
of Female Genital Tract Tumours. WHO International Histological
Classification of Tumours. 2nd edition, Springer Verlag
1994. |
| [4] |
Silverberg St G, Kurman RJ. Tumors of the
Uterine Corpus and Gestational Trophoblastic Disease.
Atlas of Tumor Pathology. AFIP Fascicle 3, 3rd edition.
1992TNM Classification of Malignant Tumours. 4th edition,
2nd revision 1992. Springer Verlag. |
| [5] |
Wittekind CH, Wagner G.TNM Klassifikation
maligner Tumoren. 5th Auflage 1997, Springer Verlag |
13.2 Originalarbeiten
| [1] |
Antunes CMF, Stolley PD, Rosenshein NB
etal. Endometrial cancer and estrogen use: Report of a
large case-control study. N Engl J Med 300: 9, 1979. |
| [2] |
Breitenecker,G., Bartl,W., Endler Margit,
Gring,H.: Die prognostische Bedeutung morphologischer
Parameter bei Endometriumkarzinomen. Onkologie 7(4):222-235,1984.
|
| [3] |
Enomoto T, Fujita M, Inoue M etal. Alterations
in the p 53 tumor suppressor gene and ist association
with activation of the c-K-ras-2 protooncogene in premalignant
and malignant lesions of the human uterine endometrium.
Cancer Res 53 (8): 1883-8, 1993. |
| [4] |
Gal D, Recio FO, Zamurovic D et al. Lymphvascular
space involvement: A prognostic indicator in endometrial
adenocarcinoma. Gynecol Oncol 42: 142-5, 1991. |
| [5] |
Gleeson NC, Gonsalves R, Bonnar J. Plasminogen
activator inhibitors in endometrial adenocarcinoma. Cancer
72(5): 1670-72, 1993. |
| [6] |
Ikeda M, Watanabe Y, Nanjoh T et al. Evaluation
of DNA ploidie in endometrial cancer. Gynecol Oncol 50
(1): 25-29, 1993. |
| [7] |
Kohler MF, Berchuck A, Davidoff AM et al.
Overexpression and mutation of p 53 in endometrial carcinoma.
Cancer Res 52 (6): 1622-27, 1992. |
| [8] |
Koshiyama M, Konishi I, Wang DP et al.
Immunohistochemical analysis of p 53 protein over-expression
in endometrial carcinomas: inverse correlation with sex
steroid receptor status. Virchows Arch A 423(4): 265-271,
1993. |
| [9] |
Kurman RJ, Norris HJ. Evaluation of criteria
for distinguishing atypical endometrial hyperplasia from
well differentiated carcinoma. Cancer 49:2547, 1982. |
| [10] |
Kurman RJ, Kaminski PF, Norris HJ. The
behavior of endometrial hyperplasia: A long-term study
of "untreated" hyperplasia in 170 patients.
Cancer 56:403, 1985. |
| [11] |
Lax SF, Piza ES, Ronnett BM, Kurman RJ.
Clear cell carcinoma of the endometrium is characterized
by a distinctive profile of p53, Ki67, estrogen and progesterone
receptor expression. Hum Pathol 1998, in press |
| [12] |
Lynch HT, Krush AJ, Larsen AL, Magnuson
CW. Endometrial carcinoma: Multiple primary malignancies,
constitional factors and heredity. Am J Med Sci 252:381,1966.
|
| [13] |
Lynch HT, Krush AJ, Thomas RJ, Lynch J.
Cancer family syndrome. in: Lynch HT ed. Cancer genetics.
Springfield Ill: Charles C Thomas pp 355-388,1976. |
| [14] |
Magriples U, Naftolin F, Shwartz PE, Carcangiu
ML. High-grade endometrial carcinoma in tamoxifen-treated
breats cancer patients. J Clin Oncol 11(3): 485-490,1993.
|
| [15] |
Parazzina F, La Vecchia C, Bocciolone L,
Francheschi S. Review: The epidemiology of endometrial
cancer. Gynecol Oncol 41:1,1991. |
| [16] |
Sherman ME, Bittermann P, Rosenschein NB,
Kurman RJ. Uterine serous carcinoma. A morphologically
diverse neoplasm with unifying clinicopathological features.
Am J Surg Pathol 16: 600-10, 1992 |
| [17] |
Sherman ME, Bur ME, Kurman RJ. p53 in endometrial
cancer and its putative precursors: evidence for diverse
pathways of tumorigenesis. Hum Pathol 26: 1268-74, 1995 |
| [18] |
Sidawy MK, Silverberg SG. Endometrial Carcinoma:
Pathological factors of therapeutic and prognostic significance.
Pathol Annu 27 (Part 2): 153-186, 1992. |
| [19] |
Tornos C, Siva EG, el-Naggar A et al. Aggressive
stage I grade 1 endometrial carcinoma. Cancer 70 (4):
790-8,1992. |
| [20] |
Uziely B, Lewin A, Brufman G et al. The
effect of tamoxifen on the endometrium. Brest Cancer Res
Treat 26(1): 101-05, 1993 |
|
